W
Winfried Gassmann
Researcher at University of Kiel
Publications - 75
Citations - 2343
Winfried Gassmann is an academic researcher from University of Kiel. The author has contributed to research in topics: Leukemia & Bone marrow. The author has an hindex of 26, co-authored 75 publications receiving 2233 citations.
Papers
More filters
Journal ArticleDOI
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
T. Büchner,Wolfgang Hiddemann,Bernhard Wörmann,Helmut Löffler,Winfried Gassmann,Torsten Haferlach,Christa Fonatsch,Detlef Haase,Claudia Schoch,Dieter K. Hossfeld,Eva Lengfelder,Carlo Aul,Axel Heyll,Georg Maschmeyer,Wolf-Dieter Ludwig,Maria-Cristina Sauerland,Achim Heinecke +16 more
TL;DR: High-dose versus standard-dose cytarabine proved a safe and effective strategy and a new way of delivering early intensification treatment for AML and may contribute a specific benefit to poor-risk patients that requires further substantiation.
Journal ArticleDOI
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Rüdiger Hehlmann,Michael Lauseker,Susanne Saußele,Markus Pfirrmann,Stefan W. Krause,Kolb Hj,Andreas Neubauer,D.K. Hossfeld,Christoph Nerl,Alois Gratwohl,Gabriela M. Baerlocher,Dominik Heim,Tim H. Brümmendorf,Alice Fabarius,Claudia Haferlach,Brigitte Schlegelberger,Martin C. Müller,Sabine Jeromin,Ulrike Proetel,Katharina Kohlbrenner,A. Voskanyan,Sebastien Rinaldetti,Wolfgang Seifarth,Birgit Spieß,Leopold Balleisen,M. C. Goebeler,Mathias Hänel,A. D. Ho,Jolanta Dengler,C. Falge,Lothar Kanz,Stephan Kremers,Andreas Burchert,Michael Kneba,Frank Stegelmann,C. A. Köhne,Hans-Walter Lindemann,Cornelius F. Waller,Michael Pfreundschuh,Karsten Spiekermann,Wolfgang E. Berdel,Lutz P. Müller,Matthias Edinger,Jiří Mayer,Dietrich W. Beelen,Martin Bentz,Hartmut Link,Bernd Hertenstein,R. Fuchs,Martin Wernli,F. Schlegel,Rudolf Schlag,M. de Wit,Lorenz Trümper,Holger Hebart,Markus Hahn,Jörg Thomalla,Christoph Scheid,Philippe Schafhausen,Walter Verbeek,Michael J. Eckart,Winfried Gassmann,Antonio Pezzutto,Michael Schenk,Peter Brossart,Thomas Geer,S. Bildat,E. Schäfer,Andreas Hochhaus,Joerg Hasford +69 more
TL;DR: In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization.
Journal ArticleDOI
Immunophenotypic and Genotypic Features,Clinical Characteristics,and Treatment Outcome of Adult Pro-B acute Lymphoblastic Leukemia:Results of the German Multicenter Trials GMALL 03/87 and 04/89
Wolf-Dieter Ludwig,Harald Rieder,Claus R. Bartram,B. Heinze,Stefan Schwartz,Winfried Gassmann,Helmut Löffler,Dieter K. Hossfeld,Gerhard Heil,Susanne Handt,Axel Heyll,H. Diedrich,K. Fischer,A. Weiss,B. Völkers,U. Aydemir,Christa Fonatsch,Nicola Gökbuget,Eckhard Thiel,Dieter Hoelzer +19 more
TL;DR: It is shown that intensification of postremission treatment may improve the prognosis of adult pro-B ALL, including patients with a t(4;11) and/or MLL-AF-4 rearrangements, and that all 7 patients treated with high-dose cytarabine and mitoxantrone as consolidation in study 04/89 remain alive and leukemia-free.
Journal ArticleDOI
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Eva Lengfelder,A. Reichert,C. Schoch,Detlef Haase,T Haferlach,Helmut Löffler,Peter Staib,Axel Heyll,Wolfgang Seifarth,Susanne Saussele,C. Fonatsch,Winfried Gassmann,W.-D. Ludwig,Andreas Hochhaus,Dietrich W. Beelen,Carlo Aul,Maria-Cristina Sauerland,Achim Heinecke,Ruediger Hehlmann,Bernhard Wörmann,Wolfgang Hiddemann,Th. Büchner +21 more
TL;DR: The results suggest that the intensity of the induction chemotherapy combined with ATRA is one of the factors which may have a critical influence on the outcome of APL and a randomized trial should assess the value of an induction therapy including ATRA and high-dose ara-C in comparison to standard-doseAra- C.
Journal ArticleDOI
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
Susanne Saußele,Marie-Paloma Krauß,Rüdiger Hehlmann,Michael Lauseker,Ulrike Proetel,Lida Kalmanti,Benjamin Hanfstein,Alice Fabarius,Doris Kraemer,Wolfgang E. Berdel,Martin Bentz,Peter Staib,Maike de Wit,Martin Wernli,Florian Zettl,Holger Hebart,Markus Hahn,Jochen Heymanns,Ingo G.H. Schmidt-Wolf,Norbert Schmitz,Michael J. Eckart,Winfried Gassmann,Andrea Bartholomäus,Antonio Pezzutto,Elisabeth Oppliger Leibundgut,Dominik Heim,Stefan W. Krause,Andreas Burchert,Wolf-Karsten Hofmann,Joerg Hasford,Andreas Hochhaus,Markus Pfirrmann,Martin C. Müller +32 more
TL;DR: Comorbidities have no impact on treatment success but do have a negative effect on OS, indicating that survival of patients with CML is determined more by comorbidity than by CML itself, and OS may be inappropriate as an outcome measure for specific CML treatments.